Analyst Impressed by Newell Rubbermaid’s CEO Performance, Polaris at Outperform, Amylin Price Target Raised

Newell Rubbermaid Inc.(NYSE:NWL): After Newell Rubbermaid reported Q4 results that Oppenheimer views as “largely mixed,” the firm notes that core sales increased 3.7%, in-line with the firm;’s forecast. The firm is impressed by the company’s performance under its new CEO, and advises investors to be “opportunistic on pullbacks,” although it maintains a Perform rating.

Polaris Industries, Inc.(NYSE:PII): After Polaris reported Q4 results that Wells Fargo views as strong, the firm believes that the company’s 2012 guidance will likely prove to be conservative, and the firm maintains an Outperform rating on the stock.

Thomas & Betts Corp.(NYSE:TNB): Baird believes the chances for the emergence of an alternative suitor with a superior offer for Thomas and Betts (NYSE:TNB) is remote. The firm cited the strategic merits of the deal with ABB (NYSE:ABB) and the premium price paid. Shares are Outperform rated and the price target is raised to $75 from $57.

Amylin Pharmaceuticals, Inc.(NASDAQ:AMLN): Baird raised its price target on Amylin following its FDA approval of Byduereon. The firm said the drug’s approval removes the company’s downside risk and makes a successful US partnership possible. Shares are Outperform rated. Piper Jaffray believes Amylin is a compelling takeout candidate following the FDA approval of Bydureon. Piper thinks the company could be acquired for $33 per share based on recent biotech acquisitions and keeps an Overweight rating on the stock.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at

To contact the editor responsible for this story: Damien Hoffman at